SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

EXCLUSIVE

Home visits are the key to patient retention, says ResearchNurses.co

By Natalie Morrison , 30-May-2012
Last updated on 30-May-2012 at 14:07 GMT

Home visits are the key to patient retention, says ResearchNurses.co
Home visits are the key to patient retention, says ResearchNurses.co
Loading...

Including home visits in clinical trial designs could be the key to patient retention, according to ResearchNurses.co.

The UK-based research nurse provider says that by providing a regular, trusted point of contact to help administer the drugs and deal with the finer details, participants are much more likely to stay in the trial.

Other benefits, says the firm, include improved patient compliance – because a trained healthcare professional is there to help administer the drug and ensure trial data is completed accurately – as well as initial clinical assessments performed before samples hit the lab.

Speaking to Outsourcing-Pharma, Sue Mackay, research nursing team manager, said: “If it does mean that we’re getting perfect data that is absolutely clean, we’re getting patient compliance and retention within the studies then in the long run that is going to benefit people.”

False economy?

Mackay added that, although the initial outlay for such individualised patient care is higher than having the patient come to the research centre, in the long-run it saves money.

To me it’s a bit of a double edge sword,” she said. “It’s one thing to recruit patients but it’s another to retain them. It would cost more to recruit all over again.

She added: “I think a lot of studies are beginning to look quite seriously at home care studies, especially for long-term diseases.”

Part II of the podcast coming up tomorrow. Mackay discusses the regulatory benefits, and changing views of Big Pharma towards home visits.

Related products

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell